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High salt (sodium) intake leads to the development of hypertension despite the fact that 
plasma sodium concentration ([Na+]) is usually normal in hypertensive human patients. 
Increased CSF sodium contributes to elevated sympathetic activity and high blood 
pressure (BP) in rodent models of hypertension. However, whether there is an increased 
accumulation of sodium in the cerebrospinal fluid (CSF) of humans with chronic 
hypertension is not well defined. Here, we investigated CSF [Na+] in samples from 
hypertensive and normotensive human subjects with family history of Alzheimer’s disease 
collected in a clinical trial, as spinal tap is not a routine clinical procedure for hypertensive 
patients. The [Na+] and osmolality in plasma and CSF were measured using flame 
photometry. Daytime ambulatory BP was monitored while individuals were awake. 
Participants were deidentified and data were analyzed in conjunction with a retrospective 
analysis of patient history and diagnosis. We found that CSF [Na+] was significantly higher 
in participants with high BP compared with normotensive participants; there was no 
difference in plasma [Na+], or plasma and CSF osmolality between groups. Subsequent 
multiple linear regression analyses controlling for age, sex, race, and body mass index 
revealed a significant positive correlation between CSF [Na+] and BP, but showed no 
correlation between plasma [Na+] and BP. In sum, CSF [Na+] was higher in chronic 
hypertensive individuals and may play a key role in the pathogenesis of human 
hypertension. Collectively, our findings provide evidence for the clinical significance of 
CSF [Na+] in chronic hypertension in humans.  




Hypertension, an important risk factor for cardiovascular disease (CVD), is the leading 
cause of death and one of the most significant public health burdens worldwide. The 
American Heart Association (AHA) estimates that hypertension affects 34% of US adults, 
or approximately 100 million individuals (7). Hypertension is independently associated 
with increased age, body mass index (BMI), race, and a high-salt diet (7, 41). In particular, 
excess dietary sodium has been linked to elevations in blood pressure (BP) (18). Previous 
studies have shown that high levels of tissue sodium are associated with a variety of 
conditions ranging from elevated BP to brain tumors, stroke, and bipolar disorder (8, 9, 
28, 36, 42, 47, 51, 55). Recent research has highlighted the importance of cerebral spinal 
fluid (CSF) sodium in regulating sympathetic activity in experimental rat (26, 37, 39) and 
mouse models (40, 53). However, data on CSF sodium concentration ([Na+]) in 
hypertensive humans is limited; thus, its clinical significance is unclear.  
We know that, over time, hypertension has harmful effects on the brain. For example, 
hypertension has been linked to an increased risk of Alzheimer’s disease (AD) later in 
life, and it has been shown that controlling BP protects against AD (6, 17, 52). Studies 
have shown that the renin angiotensin system (RAS), which regulates BP, plays a role in 
promoting AD, possibly through accumulation of the AD biomarkers, amyloid beta and 
tau protein, in CSF (3, 10). The use of BP medications that target the RAS can slow the 
conversion of mild cognitive impairment (MCI) to AD (5, 19, 57). Thus, studying the effects 
of sodium on hypertension in the middle-aged, at-risk population (i.e., those with a 
parental history of AD) is of particular clinical importance to our understanding, not only 
of AD, but also of hypertension itself and its association with sodium and eventual effects 
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on the brain. Here, we examined the relationship between sodium and BP by examining 
CSF and plasma [Na+] in middle-aged, normotensive (NTN) and hypertensive (HTN) 
humans at risk for AD.  
 
Materials and Methods 
Human subjects 
All clinical and biospecimen data in the present study were obtained at Emory University 
in Atlanta. Spinal fluid was collected from 43 middle-aged (45–65 years old) human 
subjects at risk for AD. Participants were recruited from the ASCEND (Association 
between Cardiovascular Risk and Preclinical Alzheimer’s Disease Pathology, 
ClinicalTrials.gov NCT02471833) study, an ongoing observational study among 
individuals with a parental history of AD. Participants have parents with autopsy-
confirmed or probable AD, as defined by NINDS-ADRDA criteria (38). AD diagnosis was 
verified using the validated Dementia Questionnaire and medical records, where available 
(31). Participants were free of cognitive impairment or major CVD, as determined by 
inclusion and exclusion criteria below. Relevant details of subject recruitment and 
collection of blood and CSF are also detailed below. Clinical data, including patient 
histories and diagnoses, were used in this retrospective analysis.  
Informed consent for participation in the study was obtained from all subjects in 
accordance with the human subjects Institutional Review Boards of all participating 
centers. The study was performed in accordance with the World Medical Association 
Declaration of Helsinki, International Conference on Harmonization Note for Guidance on 
Good Clinical Practice (ICH Topic E6, 1996). Study protocols were also approved by The 
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Research Integrity Offices at the University of Nevada, Reno, and Emory University, and 
the Institutional Review Board.  
Inclusion criteria (i): A biological parent with or who had AD; (ii) ≥45 years of age; (iii) 
willingness to fast for 8 hours (iv); and willingness to undergo all procedures, including 
blood draw, lumbar puncture (LP), and magnetic resonance imaging (MRI). 
Exclusion criteria (i): Contraindication for LP or MRI; (ii) significant neurological disease, 
(iii) heart failure, (iv) type I or II diabetes, (v) history of significant head trauma, (vi) major 
depression within the past 2 years, (vii) HIV/AIDS, (viii) history of alcohol or substance 
abuse, (ix) significant systemic illness or unstable medical condition that could affect 
cognition or cause difficulty complying with or completing the protocol, (x) diagnosis of 
AD, (xi), subjective cognitive impairment (MCI) or residence in a skilled nursing facility, 
(xii) use of another investigational medication or AD medication, or (xiii) unwillingness to 
fast. 
Ambulatory BP monitoring  
Ambulatory BP monitoring (ABPM) has many advantages in relation to clinic BP 
measurement since it is conducted while individuals perform their normal daily activities 
and because it provides estimates of BP over the entire monitoring period, including 
separately during nighttime and daytime (56). BP was measured every 20 minutes while 
participants were awake. Ambulatory BP endpoints included mean daytime ambulatory 
BP (systolic and diastolic). Ambulatory measures provide superior predictive value for 
cardiovascular events compared with BP measurements in the clinic and have been used 
in dementia research(50).  
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Participants were separated into normotension or hypertension groups according to their 
diagnosis and awake ABPM, as summarized in Table 1. They were further sub-
categorized as Normal BP (systolic BP [sBP]<120 mmHg and diastolic BP [dBP]<80 
mmHg), Elevated BP (120≤sBP≤129 mmHg and dBP<80 mmHg), HTN-Stage 1 
(130≤sBP≤134 mmHg or 80≤dBP≤84 mmHg), or HTN-Stage 2 (sBP≥135 mmHg or 
dBP≥85 mmHg) according to the 2017 High Blood Pressure Clinical Practice Guideline 
(HBPCPG) of the American College of Cardiology and American Heart Association (56). 
Participant data were de-identified, and measurements of plasma and CSF [Na+] were 
performed in a blinded fashion.  
CSF collection 
CSF samples were acquired by LP after an 8-hour overnight fast according to the 
guidelines put forth in the “Biospecimens Best Practice Guidelines for the ADCs”, 
published by the National Alzheimer's Coordinating Center (NACC). Participants were 
placed in a sitting position and asked to maximally flex their knees, hips, back, and neck. 
The skin over L4-L5 was prepped and draped in a sterile manner; 1% lidocaine was used 
as a local anesthetic, followed by insertion of a spinal needle with introducer into the L4-
L5 interspace using sterile technique. Approximately 22 ml of CSF was collected into 
sterile polypropylene collection tubes using a 24-gauge Sprotte needle and a gentle 
extraction technique. Samples were centrifuged at 2500 rpm for 10 minutes, then 
aliquoted into 500 µL polypropylene cryovials and stored at -80°C for assay after all 
participants had been sampled.   
Blood collection  
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Blood was drawn from participants after an 8-hour overnight fast, and plasma was 
collected for [Na+] measurements. Blood and CSF samples were obtained during the 
same study visit.  
Flame photometer measurement of [Na+] in plasma and CSF 
The [Na+] in plasma and CSF samples obtained from study participants was determined 
using a flame photometer (Model ISE IL 943; GMI Inc., Ramsey, MN, USA). The method 
was calibrated and performed according to the manufacturer's specifications using quality 
controls.  
Plasma and CSF osmolality measurements 
Plasma and CSF osmolality was measured with an Advanced Micro Osmometer (Model 
3300; Advanced Instruments, Norwood, MA, USA), which was maintained in a dry room 
with a steady room temperature, as recommended by the manufacturer. Calibration was 
carried out as per instructions using 50 and 850 mOsm/kg H2O standards. Twenty 
microliters of human plasma and CSF samples were used for these measurements. A 
Clinitrol 290 mOsm/kg H2O reference solution (Ref. 3MA029; Advanced Instruments) was 
used to evaluate and ensure the performance of the instrument. Measurements were only 
accepted if the control provided a result of 290±2 mOsm/kg H2O, as per the calibration 
instructions provided.  
 
Statistical analysis 
Data are expressed as means ± standard error of the mean (SEM). Data were analyzed 
using Student’s t-test or one-way analysis of variance (ANOVA) with Bonferroni post hoc 
tests to compare replicate means, as appropriate, using Prism8 (GraphPad Software, 
 
 8 
San Diego, CA, USA). Multiple linear regressions were performed using SAS 9.4. All 
statistical tests were two-tailed, and differences were considered statistically significant 
at P<0.05.  
 
Results 
Subject characteristics  
Participants were divided into two groups based on daytime ABPM, as outlined in Table 
1. Participants in the normotension group (n=25) were defined as those with sBP < 130 
mmHg and dBP < 80 mmHg with no previous history of hypertension diagnosis, whereas 
those in the hypertension group (n=18) had sBP ≥ 130 mmHg or a dBP ≥ 80 mmHg, and 
a history of hypertension diagnosis. Racial and gender profiles of both groups were 
similar; however, BMI was significantly higher in the high BP group (P<0.05). There were 
more females than males in both groups (~75% in the Normal BP group and 62% in the 
High BP group), but there was no significant difference in systolic (120±3.2 vs. 123.5±2.6 
mmHg, P=0.4959) or diastolic (77.6±1.5 vs. 75.1±1.7 mmHg, P=0.4361) BP between 
male and female participants. Some subjects were currently using antihypertensive drugs 
(Table 2), and medications used by subjects were not withheld. Because salt sensitivity 
and hypertension rates increase in women after menopause, it is important to highlight 
that only 5 of a total of 33 women reported being on hormone replacement therapy. Since 
this percentage is small and the BP, CSF or plasma [Na+] values of these individuals were 
not outliers, we did not further segregate female subjects into different groups.  
 
Increased CSF [Na+] in hypertensive humans  
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To determine if sodium levels in the CSF are higher in hypertensive humans, we analyzed 
CSF [Na+] in normotensive and hypertensive participants (Table 1). As expected, we 
found an increase in the average sBP and dBP in the hypertension group compared with 
the normotension group (Figure 1A and 1B). Importantly, we found a significant elevation 
in CSF [Na+] in hypertension participants compared with those in the normotension group 
(148.8±3.4 mM vs. 138.1±1.9 mM, P=0.0053), as shown in Figure 1C. In contrast, plasma 
[Na+] was similar between the two groups (Figure 1D). There was no difference in CSF 
potassium concentration ([K+]) between groups (Figure 1E). 
To further determine whether CSF [Na+] was related to hypertensive stage, we divided 
study participants into four sub-groups according to 2017 HBPCPG guidelines (56). As 
expected, sBP (Figure 2A) was significantly higher in Elevated BP (P<0.01), HTN-Stage 1 
(P<0.0001), and HTN-Stage 2 (P<0.0001) subjects compared with individuals with normal 
BP; whereas dBP (Figure 2B) was significantly higher in HTN Stage 1 (P<0.05) and HTN 
Stage 2 (P<0.0001) subjects compared with normal BP individuals. Interestingly, we 
found that CSF [Na+] was significantly higher specifically in HTN-Stage 2 subjects 
(155.7±6.8 mM; P=0.0051) compared with all other groups (Figure 2C). There was a 
tendency toward higher CSF [Na+] in HTN-stage 1 subjects (144.8±3.1 mM) compared to 
individuals with normal BP (139.3±2.5 mM), but this difference did not reach statistical 
significance. As shown in Figure 2D, we found no difference in plasma [Na+] among 
groups. 
Human CSF [Na+] is positively correlated with BP 
Distinct gender differences in the incidence and severity of human hypertension are well 
established; race, age, and BMI are also factors known to affect BP (16, 33, 34). As shown 
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in Table 1, our study population contained more females than males. In addition, BMI was 
significantly higher in hypertensive subjects and was correlated with BP (Figure 3). To 
accurately determine correlations between CSF or plasma [Na+] and sBP or dBP, we 
performed a multiple regression analysis between [Na+] and BP, controlling for age, sex, 
race, and BMI. As shown in Table 3 and the regression curves in Figure 4A and 4B, [Na+] 
in CSF was positively correlated with sBP (R2=0.4189, P=0.0007) and dBP (R2=0.205, 
P=0.032). Interestingly, we identified a significant contribution of BMI to sBP (P=0.005), 
but not dBP (P=0.102) (Table 3 and Figure 3). We found no correlation between plasma 
[Na+] and sBP (R2=0.0009, P=0.9759) or dBP (R2=0.0222, P=0.2995), as shown in Table 
3 and the linear regression curves presented in Figure 4C and 4D. To determine whether 
the elevation in CSF [Na+] was caused by higher plasma [Na+] in each individual, we 
performed linear regression analyses. These analyses showed no correlation between 
plasma and CSF [Na+] (R2=0.0002174, P=0.9252; Figure 4E), suggesting that the 
elevation in CSF [Na+] is not attributable to passive diffusion from the circulation, and 
instead indicates that active transport mechanisms may be involved in elevating CSF 
[Na+]. Collectively, our results indicate that CSF [Na+] is positively correlated with BP, 
whereas plasma [Na+] is not.  
Osmolality is not affected by increased [Na+] in CSF 
We further analyzed CSF and plasma osmolality in normotension and hypertension 
groups and were surprised to find no difference in either CSF or plasma osmolality 
between the two groups (Figure 5A and 5B). Furthermore, there was no difference in CSF 
or plasma osmolality between groups at different hypertensive stages (Figure 5C and 
5D), indicating that CSF [Na+] may be more clinically relevant than CSF osmolality in the 
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pathogenesis of chronic hypertension. Notably, plasma and CSF osmolality were not 
correlated with sBP or dBP (Figure 5E–5H).  
 
Discussion 
High levels of dietary sodium are associated with elevated BP and adverse effects on 
cardiovascular health (11). Animal experiments, epidemiological studies, and clinical 
trials have provided compelling evidence for a detrimental effect of sodium intake on BP 
in both HTN and NTN individuals (1, 44). In addition to its effects on BP, excess dietary 
sodium consumption has been directly linked to coronary heart disease (12, 24), stroke 
(2) and non-cardiovascular diseases (4). Nevertheless, data on CSF and plasma [Na+] in 
HTN humans is limited and its significance in cardiovascular health remains 
undetermined. Only one study with a small sample size has investigated the association 
between CSF or plasma [Na+] and BP in young hypertensive humans consuming their 
normal, habitual diet (29). In this study, we found a significant increase in CSF [Na+], but 
not plasma [Na+], in hypertensive participants compared with normal BP individuals, 
suggesting the importance of CSF [Na+] in human hypertension. We further showed that 
CSF [Na+] is positively correlated with both systolic and diastolic BP in human subjects 
on their normal diet.  
 
It has been suggested that small increases in plasma [Na+] may be a mechanism by which 
dietary salt raises BP (15, 21, 48); however, our data showed no correlation between 
plasma [Na+] and BP in normal or high BP individuals under a habitual diet. The 
conclusion that plasma [Na+] is linked to BP in humans is mostly based on acute effects 
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of dietary sodium intake (15, 48). For example, in both NTN and HTN humans, a large 
and sudden increase in dietary sodium causes a 2- to 4-mM rise in plasma [Na+] (25, 30, 
43, 49). Studies of gradual increases or decreases in salt intake have similarly shown 
increases or decreases in plasma [Na+], respectively, of approximately 3 mM after 5 days 
of treatment and reported a significant relationship between the increase in plasma [Na+] 
and an increase in pulse pressure (22, 23, 45). In humans, the effect of an abrupt increase 
in sodium intake for 5 to 28 days on BP is also related to age; in younger subjects (<26 
years of age), BP and plasma [Na+] do not rise (25, 32). In contrast, in individuals over 60 
years old, an acute increase in sodium intake is associated with a rise in plasma [Na+] of 
1.6 to 3 mM and an increase in mean arterial pressure (27, 30). These reports support 
the effects of acute high-salt intake on plasma [Na+] and BP regulation. Nevertheless, an 
elegant commentary by Wardener et al. (15) that summarized seven independent studies 
on baseline plasma [Na+] in a total of 108 NTN and 57 HTN humans concluded that there 
were no obvious differences in plasma [Na+] between NTN and HTN subjects. The 
changes in plasma [Na+] reported in our study are in the same range, and our overall 
findings agree with these reports indicating no correlation between plasma [Na+] and BP 
in humans.       
An important finding from this study is that CSF [Na+], but not plasma [Na+], is significantly 
correlated with BP in humans on their natural, habitual diet. To date, there have been 
only few independent reports on CSF [Na+] in HTN humans (20, 29, 30). In one study, 
Kawano et al. examined CSF [Na+] levels in 15 patients with essential hypertension on a 
high-salt diet (16–18 g/d) compared with a low salt diet (1–3 g/d) for 7 days. They reported 
that [Na+] was significantly elevated in both CSF and serum during the high-salt-diet 
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period compared with the low-salt-diet period (30). In another study, 24 hypertensive 
individuals were provided 7 g or 25 g of daily dietary salt during low- and high-salt intake 
periods, respectively, for 7 days each. The authors of this study concluded that changes 
in CSF [Na+] were related to the patient’s salt sensitivity. With a daily salt intake of 25 g/d, 
CSF [Na+] significantly increased in 13 salt-sensitive patients compared with salt-resistant 
individuals. However, the 7 g/d dietary salt regimen did not affect CSF [Na+] in any of the 
patients (20). Although these studies did not perform correlation analyses of CSF [Na+] 
and BP, taken together with our data, they indicate that elevated CSF [Na+] might be a 
key mechanism by which sodium raises BP in humans. Our results provide the direct 
demonstration of a positive correlation between CSF [Na+] and BP in humans. The 
mechanism by which a high-salt diet elevates CSF [Na+] remains an important topic for 
future studies. 
In this study, the daily intake of sodium was not monitored. However, the main focus of 
this study was on examining the levels of sodium in CSF versus plasma in populations 
on their regular habitual diets regardless of the cause (e.g., relative sodium intake, renal 
dysfunction). In addition, the increase in CSF [Na+], but not plasma [Na+], suggests 
important unknown mechanisms for active sodium re-distribution (accumulation) in the 
CSF in hypertension, which is a key finding of this study. Our finding that plasma and 
CSF [Na+] were not correlated with each other also supports our hypothesis of enhanced 
active transport or retention of sodium in the CSF of HTN humans. CSF—the fluid in the 
brain ventricles and spinal cord—is predominantly, but not exclusively, produced by the 
choroid plexus. CSF plays an important role in protecting the brain and regulating brain 
interstitial electrolyte and fluid homeostasis (46). It has been shown that several sodium 
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transporters and antiport systems regulate CSF sodium (35). Among them, the Na-K-
ATPase is probably the main transporter of sodium from the epithelium to CSF (35), 
whereas movement of sodium from CSF to the blood or interstitial space is mediated 
primarily by epithelial sodium channels (54). Whether there are changes in sodium 
transporters and/or the biophysical properties of these channels during the development 
of human hypertension remains to be determined. We propose that the increase in 
sodium levels in CSF might be related to dysfunction of the processes that redistribute or 
actively transport sodium into the brain, possibly in combination with an inadequacy of 
kidney sodium excretion or pressure diuresis mechanisms (13, 14).  
One limitation of this study is that the subjects all have a family history of AD. Because, 
in current clinical practice, spinal tap is not a routine procedure for hypertensive patients 
without other complications, it is clinically difficult to justify and challenging to carry out 
such a study in this patient population. To achieve our goal, we chose this population, 
which is otherwise healthy but with a family history of AD, for both hypertensive and 
normotensive groups. Since all subjects in this study have a family history of AD, we 
believe that the data obtained reflect the relationship between CSF sodium and BP. 
However, we acknowledge that the observed elevation in CSF Na+ and the positive 
correlation of CSF Na+ with BP may be more significant in hypertensive patients with 
family history of AD, and may or may not be universal among regular hypertensive 
subjects.   
Interestingly, when the subjects were subdivided into different groups according to their 
BP levels (Normal BP, Elevated BP, HTN Stages 1 and 2), we found that CSF [Na+] was 
significantly higher only in HTN Stage 2 subjects. Although there was a trend toward an 
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increase in CSF [Na+] in HTN Stage 1 subjects, this difference was not statistically 
significant, possibly due to the small sample size. On the other hand, since CSF [Na+] 
was not increased in earlier stage HTN, another possibility is that CSF [Na+] may reflect 
high BP-induced compromised BBB integrity or altered sodium transport resulting from 
HTN. Whether elevated CSF sodium is a cause or result of human hypertension needs 
further investigation.    
In conclusion, our data show a significant increase in CSF [Na+], but not plasma [Na+], in 
HTN patients with a family history of AD that is positively correlated with BP, suggesting 
the potential importance of CSF Na+, but not plasma Na+, in the development or 
maintenance of chronic human hypertension. Our findings thus support the biological 
plausibility of a functional relationship between high sodium in the CSF and arterial 
pressure in humans, although the underlying mechanisms remain to be determined.  
 
Clinical Perspectives 
High dietary sodium intake is associated with elevated BP and adverse effects on 
cardiovascular health. The importance of CSF sodium in the regulation of sympathetic 
activity has been highlighted by recent experimental animal studies. However, the clinical 
significance of CSF sodium in hypertensive humans is not clear. In this study, we show 
that CSF sodium concentration is increased in hypertensive compared to normotensive 
individuals with family history of AD and that CSF sodium concentration is positively 
correlated with blood pressure. It is important to understand the mechanisms associated 
with the increase in CSF sodium concentration in hypertensive individuals, and to 
determine whether the elevated CSF sodium is the cause of high blood pressure, or 
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simply a phenomenon that accompanies the hypertension. Addressing these questions 
will be important for advancing our understanding of hypertension development and may 
contribute to the discovery of new therapeutics for hypertension. 
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Values are presented as means±SEM. *P<0.05, ****P<0.0001 vs. Normal BP group; 







Table 2. Antihypertensive drugs used in Stage 1 and Stage 2 hypertensive subjects 
 
Antihypertensive drugs HTN Stage 1 
(n=11) 
HTN Stage 2 
(n=7) 
ACE inhibitors (n) 0 1 
CC blockers (n) 0 1 
Beta blockers (n) 1 1 
Diuretics (n) 0 2 
AT1 receptor antagonists (n) 0 1 
 
Abbreviations: ACE, angiotensin converting enzyme; CC, calcium channels; Beta, β-
















(n = 25) 
Hypertension 
(n = 18) 
Demographics   







Age (years) 60.61.09 62.01.4 
BMI (kg/m2) 25.81.0  30.11.4* 
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Table 3. Multiple regressions between plasma or CSF [Na+] and sBP or dBP, controlling 
for age, sex, race, and BMI   
 




SEM t-value Pr>|t| 
Intercept 1 21.75612 27.96648 0.78 0.4416 
CSF [Na+] 1 0.50138 0.13580 3.69 *0.0007 
Age 1 0.06915 0.32899 0.21 0.8347 
Sex 1 -1.80857 4.29869 -0.42 0.6764 
Race 1 -2.81272 3.80568 -0.74 0.4645 
BMI 1 0.97866 0.32867 2.98 *0.0051 




SEM t-value Pr>|t| 
Intercept 1 30.75332 20.85935 1.47 0.1489 
CSF [Na+] 1 0.22576 0.10129 2.23 *0.032 
Age 1 0.01925 0.24539 0.08 0.9379 
Sex 1 3.35840 3.20626 1.05 0.3017 
Race 1 -1.22560 2.83854 -0.43 0.6684 
BMI 1 0.41123 0.24515 1.68 0.1019 




SEM t-value Pr>|t| 
Intercept 1 92.14064 77.68614 1.19 0.2432 
Plasma [Na+] 1 -0.01595 0.52365 -0.03 0.9759 
Age 1 0.09842 0.39147 0.25 0.8029 
Sex 1 -5.00660 4.93816 -1.01 0.3172 
Race 1 -0.95823 4.43967 -0.22 0.8303 
BMI 1 1.03084 0.38856 2.65 *0.0117 




SEM t-value Pr>|t| 
Intercept 1 113.32486 51.98281 2.18 0.0357 
Plasma [Na+] 1 -0.36870 0.35039 -1.05 0.2995 
Age 1 -0.01754 0.26195 -0.07 0.9470 
Sex 1 1.67961 3.30431 0.51 0.6143 
Race 1 -0.05791 2.97075 -0.02 0.9846 
BMI 1 0.47508 0.26000 1.83 0.0757 
Abbreviations: df, degrees of freedom; SEM, standard error of the mean; CSF, 
cerebrospinal fluid; [Na+], sodium concentration; sBP, systolic blood pressure; dBP, 






Figure 1. Increased [Na+] in the CSF of high BP patients. (A, B) sBP (A) and dBP (B) 
of study subjects. (C, D) CSF [Na+] (C) and plasma [Na+] (D) in study subjects. (E) CSF 
[K+] in study subjects. Normotension, n=25; Hypertension, n=18; **P<0.01, ****P<0.0001 
vs. Normotension; unpaired t-test. 
 
Figure 2. Increased CSF [Na+] in HTN stage 2 patients. (A, B) sBP (A) and dBP (B) of 
study subjects. (C, D) CSF [Na+] (C) and plasma [Na+] in study subjects (D). Normal BP, 
n=20; Elevated BP, n=5; HTN-Stage 1, n=11; HTN-Stage 2, n=7; *P<0.05, **P<0.001, 
****P<0.0001 vs. Normal BP group; ##P<0.01, ####P< 0.0001 vs. HTN-Stage 1 group; one-
way ANOVA with Bonferroni post hoc tests. 
 
Figure 3. Elevated BP in hypertensive participants. (A, B) Correlation of sBP (A) and 
dBP (B) with BMI (n=43). ** P<0.01; linear regression. (C) BMI of study subjects. Normal 
BP, n=20; Elevated BP, n=5; HTN-Stage 1, n=11; HTN-Stage 2, n=7; *P<0.05, vs. Normal 
BP group; one-way ANOVA with Bonferroni post hoc tests. 
 
Figure 4. Human CSF [Na+] is positively correlated with BP. (A, B) Correlation of sBP 
(A) and dBP (B) with CSF [Na+]. (C, D) Correlation of sBP (C) and dBP (D) with plasma 





Figure 5. Human CSF and plasma osmolality are not correlated with BP. (A, B) CSF 
and plasma osmolality in normal and high BP. N=25 (Normotension) and 18 
(Hypertension), unpaired t test. (C, D) CSF and plasma osmolality in study subjects 
subdivided according to BP levels. Normal BP, n=20; Elevated BP, n=5; HTN-Stage 1, 
n=11; HTN-Stage 2, n=7, One-way ANOVA with Bonferroni post hoc tests. (E, F) 
Correlation of sBP (C) and dBP (D) with CSF osmolality (n=37). (G, H) Correlation of sBP 
(E) and dBP (F) with plasma osmolality (n=38), linear regression.  
